Ibrutinib is an oral inhibitor of Bruton tyrosine kinase (BTK) with marked activity in several B-cell malignant neoplasms.
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Commonly reported adverse events include diarrhea, infection, fatigue, arthralgias, pyrexia, hypertension, and neutropenia. 2 Grade 1 and 2 rashes have been described but are generally self-limited and not treatment limiting. To our knowledge, panniculitis, an inflammation of the subcutaneous adipose tissue, has not yet been described during ibrutinib therapy. We describe 5 patients who developed panniculitis during ibrutinib treatment for lymphoid leukemias.
Methods | We conducted an institutional review boardapproved retrospective medical record review to identify patients with ibrutinib-associated panniculitis at a single academic center. Due to its retrospective nature, the study was Abbreviations: ALC, absolute lymphocyte count; ANC, absolute neutrophil count; CLL, chronic lymphocytic leukemia; FISH, fluorescence in situ hybridization; GMS, Grocott methenamine silver; HCL, hairy cell leukemia; IgG, immunoglobulin G; NA, not available; SLL, small lymphocytic lymphoma; WBC, white blood cell. Results | Five patients were identified (Table) , all of whom developed isolated painful, nodular rashes, primarily on the extremities, while receiving ibrutinib ( Figure, A and B) . Histopathologic analysis demonstrated a lobular and septal panniculitis, frequently with superficial and perivascular mixed inflammatory infiltrate and prominent leukocytoclasis ( Figure,  C and D) . Three patients received oral prednisone in low, tapering doses. Gradual tapering of the prednisone dose resulted in sustained resolution of the rash in 1 patient (case 4) but recurrence after discontinuation of corticosteroid use in the remaining 2, both of whom required sustained maintenance therapy. Among patients not receiving steroids, the rash was either relapsing and remitting (case 2) or persistent (case 5).
Discussion | Cutaneous eruptions are common among patients with lymphoid malignant neoplasms. The differential diagnosis is broad, including infectious, immunologic, paraneoplastic, and iatrogenic etiologies. Panniculitides have been reported in association with use of some chemotherapeutics, although primarily neutrophilic and more typical in myeloid disorders. 3 Because panniculitis may mimic extensive atypical purpura, which is common during ibrutinib treatment, biopsy may be required for diagnosis. Careful clinicopathologic evaluation, including tissue culture for bacterial, fungal, and acid-fast organisms, is important. Although our patients differed by diagnosis, treatment history, and immune status, they generally presented with painful erythematous nodules involving the extremities early in the course of ibrutinib therapy. Diagnosis of this unique entity is aided by its distinct pattern of distribution, absence of systemic symptoms, and histopathological pattern of lymphohistiocytic, lobular panniculitis with prominent leukocytoclasis and occasional eosinophils. Use of low-dose systemic corticosteroids resulted in complete resolution of cutaneous manifestations. The rash has yet to prove treatment limiting, but patients may require sustained low-dose prednisone therapy for suppression while receiving ibrutinib. Use of nonsteroidal anti-inflammatory drugs may mitigate symptoms.
Whereas the mechanism underlying ibrutinib-associated panniculitis has not been fully elucidated, its histopathologic features are reminiscent of a localized adaptive cellular immune response against a novel hapten epitope. 4 It is conceivable that ibrutinib-conjugated peptides are presented to host immune cells via major histocompatibility complex, leading to a T-cell-driven immune response and bystander tissue destruction. Whereas ibrutinib was designed to bind and inhibit BTK, the drug binds a broad range of cellular kinases at therapeutic doses, including the inducible T-cell kinase. Inhibition of inducible T-cell kinase may modulate cellular immunity, potentially contributing to the development of panniculitis. 5 Furthermore, 
Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in BRAF-Mutant Colorectal Cancer
Axillary lymph nodes (axLNs) are a virtually unheard of site of metastasis in patients with metastatic colorectal cancer (mCRC). Our search of the National Library of Medicine's PubMed database identified only 6 case reports, 1-6 each describing 1 patient with axLN metastasis of primary colorectal cancer ( Table 1) .
Methods | Initially, we identified 3 cases of axLN metastasis clinically in patients with CRC, and all were noted to have BRAF-mutant mCRC.
Since late 2008, all mCRCs in our institution have been sequenced for KRAS and BRAF mutations. We therefore identified all cases with BRAF mutation between 2008 and 2012 and reviewed clinical and radiology records for evidence of axLN metastases. For a comparison group, we performed a computerized search for patients with mCRC whose tumors were genotyped in 2011 and identified the first 100 sequential cases with wild-type BRAF.
All cases were reviewed for axillary lymphadenopathy on imaging studies in the absence of additional primary malignant neoplasms to describe the frequency of axLNs larger than 1 cm in these patients. Appropriate Memorial Sloan Kettering Cancer Center institutional review board and/or privacy board waivers were obtained for this review.
Results | Three patients identified during their clinical course had biopsy confirmation of CRC metastases to the axilla. Patient 1, a woman in her 30s, presented with mCRC involving the peritoneum and ovaries treated with complete cytoreduction. She developed a rapid recurrence in the peritoneum, LNs, and pleura, with concurrent increase in size and number of left 
